Ticker

First peer-reviewed publication of chemotherapy-resistant gamma-delta T cells (DeltEx Drug Resistant Immunotherapy or DRI) clinical results in newly diagnosed glioblastoma Repeat-dose patients achieved median progression-free survival (mPFS) of 16.1 months, more than double the ~6.9-month standard of care benchmark, with no dose-limiting toxicities (DLTs) NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc.…

DRI enters fiscal 2027 with growth from LongHorn, digital initiatives and new restaurants, while inflation and cautious spending test margins.

Darden combines earnings growth, cash returns and a lower valuation multiple, but estimate cuts and inflation keep investors weighing the stock's outlook.

DRI is balancing digital growth, brand diversification and value-focused pricing as inflation and consumer spending trends shape its margin outlook.

In this article series, I summarize dividend announcements of the past week. Thirteen companies in my database (including 7 banks) announced dividend increases. JPMorgan Chase stands out with a 10% dividend hike, an A+ safety grade, and a new $50B buyback, and trades only 3.35% above fair value. Matson is the week's high-quality non-bank, boasting a 7.34 quality score, 9.4 safety score, and a conservative 10% payout…